First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - Springer
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …
被引用次数：24 相关文章

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

L Thierry, C Kader, D Boris… - Journal of Cancer …, 2020 - search.proquest.com
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

T Landre, G Des Guetz… - Journal of cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor-receptor (EGFR) mutation. Addition …

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - search.ebscohost.com
Purpose: Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition …

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - europepmc.org
Purpose Erlotinib is indicated as first-line treatment for patients with non-small-cell lung
cancer (NSCLC) harboring an epidermal growth-factor-receptor (EGFR) mutation. Addition …